ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) shares dropped 5.8% during mid-day trading on Monday . The stock traded as low as $1.68 and last traded at $1.70. Approximately 1,719,315 shares were traded during mid-day trading, a decline of 54% from the average daily volume of 3,755,635 shares. The stock had previously closed at $1.80.
ImmunityBio Price Performance
The firm has a 50 day moving average of $2.02 and a two-hundred day moving average of $2.34.
ImmunityBio (NASDAQ:IBRX – Get Free Report) last issued its earnings results on Tuesday, August 8th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. Equities analysts predict that ImmunityBio, Inc. will post -1.04 EPS for the current fiscal year.
Institutional Trading of ImmunityBio
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.
- Five stocks we like better than ImmunityBio
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in Biotech Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.